| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Achieve Life Sciences, Inc.$6.11
-0.38 (-5.94%)
B 61Pipeline Score Undervalued Biotech · Commercial
Market Cap
516.38 M
EPS
-1.12
P/E Ratio
-4.51 $
Value Trade
6.58 M
SEC Financials
Q1 2026Dilution Risk
40%Operating CF
-6.93 M
Total Assets
33.10 M
Total Liabilities
22.43 M
Equity
10.68 M
D/E Ratio
12,345
-16.25 %
Week
9.07 %
1 Month
8.82 %
3 Month
19.95 %
6 Month
-49.3 %
5 Year
-100 %
All Time
Cash Data
Cash Position
29.27 M
Monthly Burn
2.31 M
Runway
11 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
2.05 M
52 Week Range
2 - 6.15
% held by Insiders
22.57 %
% held by Institutions
22.38 %
Enterprise Value
502.06 M
Total Shares
53.20 M
Short %
32.18 %
Float Shares
39.10 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Achieve Life Sciences, Inc.
471Total events
3Upcoming
99Tier-1 (high impact)
2008 – 2027Coverage
Upcoming catalysts 3
Event history 468
Jun 22, 2026
▼Complete Response LetterCytisiniclineFDA Decision
FDA issued Complete Response Letter for cytisinicline NDA due to manufacturing facility deficiencies
nicotine dependence (smoking cessation)source ↗
Jun 20, 2026
◆PDUFA DateCytisiniclineRegulatory Filing
PDUFA target action date of June 20, 2026 for smoking cessation NDA
nicotine dependence for smoking cessationsource ↗
Jun 2, 2026
▲Management ChangeCorporate
Appointment of Jeffrey Farrow and Reid Waldman, MD to Board of Directors
May 12, 2026
May 12, 2026
●Manufacturing MilestoneCytisiniclineCMC / Inspection
Advances U.S.-based manufacturing transition and partnership with Adare Pharma Solutions
nicotine dependencesource ↗
May 2026
●Oral PresentationCytisiniclinePresentation
Long-term safety data presented at ATS International Conference
nicotine dependence (smoking cessation)source ↗
Apr 17, 2026
Apr 2026
▼Equity OfferingCorporate
Closed private placement of up to $354 million, including $180 million upfront and $174 million in milestone-driven warrants
Drug Pipeline Intelligence
B61
Pipeline Score $2.5B
Pipeline ValueUndervalued
Valuation Signal8
Drugs Scored15.0x
rNPV / MCap Top 89%
Micro Cap (rank 101 of 911)
Percentile RankAchieve Life Sciences, Inc. holds a solid B-grade pipeline (61/100), with $10.5B risk-adjusted pipeline value, led by Cytisinicline in Smoking Cessation (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytisinicline Small molecule | Vaping Cessation | Phase 3 | NCT07392125 | 79% | $2.8B | NOT YET_RECRUITING | 800 | VERY_FAST | B (64) | Sep 30, 2027 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
cytisinicline Breakthrough | smoking cessation | Phase 3 | 2026-03-04 | 6 and 12 weeks of cytisinicline delivers meaningful quitting success, regardless of participants' prior use of smoking cessation medications or number of previous quit attempts. Read More | Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study Read More | |
cytisinicline Breakthrough | smoking cessation | Phase 3 | 2026-03-04 | 6 and 12 weeks of cytisinicline delivers meaningful quitting success, regardless of participants' prior use of smoking cessation medications or number of previous quit attempts. Read More | Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study Read More | |
cytisinicline Breakthrough | smoking cessation | Phase 3 | 2026-03-04 | 6 and 12 weeks of cytisinicline delivers meaningful quitting success, regardless of participants' prior use of smoking cessation medications or number of previous quit attempts. Read More | Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACHV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ACHV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ACHVAchieve Life Sciences Joins Russell 2000® Index
Achieve Life Sciences has been added to the Russell 2000 Index as of June 26, 2026. This inclusion is significant as the Russell 2000 Index is a key benchmark for small-cap U.S. equities, potentially increasing the company's visibility among institutional investors. Achieve focuses on developing cytisinicline for nicotine dependence, supported by successful clinical studies.
Read more →ACHV▲ +5.2%on this news· ran to +18% by day 3
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
Achieve Life Sciences received a Complete Response Letter from the FDA for its cytisinicline NDA, citing manufacturing deficiencies but no safety or efficacy issues. The company plans to resubmit its application in Q4 2026 after addressing these concerns. Cytisinicline has shown promising results in clinical trials for smoking cessation.
Read more →ACHV▼ -5.1%on this news
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Achieve Life Sciences has appointed Jeffrey Farrow and Dr. Reid Waldman to its Board of Directors as the company prepares for the NDA resubmission of cytisinicline, a treatment for nicotine dependence. Both appointees bring extensive experience in biotech and pharmaceutical launches, which is crucial as Achieve aims to deliver a new smoking cessation therapy. The company is positioned at a pivotal moment with promising clinical data supporting cytisinicline's efficacy.
Read more →ACHVAchieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
Achieve Life Sciences presented long-term safety data for cytisinicline at the ATS 2026 Annual Meeting. The ORCA-OL study involved 475 adults and demonstrated a favorable safety profile over 52 weeks. Despite some adverse events, the majority were mild. The findings support the company's New Drug Application for cytisinicline as a treatment for nicotine dependence.
Read more →ACHV▲ +7.2%on this news
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
Achieve Life Sciences has announced three senior leadership appointments, including Christopher Martin to the Board and Mark Zappia and Jim Willis to key commercial roles. These appointments follow the recent appointment of Dr. Andrew D. Goldberg as CEO and a significant financing round. The company aims to commercialize cytisinicline, a potential new treatment for nicotine dependence, as it prepares for FDA approval.
Read more →ACHV▲ +7.2%on this newsshared move
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
Achieve Life Sciences reported its first quarter 2026 financial results, highlighting significant advancements in its development of cytisinicline for nicotine dependence. The company secured up to $354 million in financing to support its Phase 3 trial for e-cigarette cessation and announced leadership changes. Achieve anticipates resubmitting its New Drug Application by Q4 2026, aiming for a U.S. commercial launch in early 2027.
Read more →ACHV▲ +7.2%on this newsshared move
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrant
Achieve Life Sciences reported its first quarter 2026 financial results and announced a private placement of up to $354 million, including $180 million upfront. The company appointed a new CEO and expanded its board while advancing its U.S. manufacturing transition. Achieve aims to launch cytisinicline, a treatment for nicotine dependence, pending FDA approval expected by June 20, 2026. The financial results reflect a net loss of $10.2 million for the quarter, while cash reserves were reported at $29.3 million, not counting the upcoming financing.
Read more →ACHVAchieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026
Achieve Life Sciences will announce its first quarter 2026 financial results on May 12, 2026, along with a corporate update. The company is focused on the development of cytisinicline for nicotine dependence, with an FDA review underway for its New Drug Application submitted in June 2025. The FDA has set a PDUFA date of June 20, 2026.
Read more →ACHV▲ +35.5%on this news
Achieve Life Sciences Announces Up to $354 Million Private Placement
Achieve Life Sciences has announced a private placement agreement to raise up to $354 million, aimed at funding a Phase 3 clinical trial for cytisinicline, a treatment for nicotine dependence. The placement involves new and existing investors and will close on April 17, 2026. Additionally, Dr. Andrew D. Goldberg has been appointed as the new CEO, bringing extensive healthcare expertise.
Read more →ACHV▲ +35.5%on this newsshared move
Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors
Achieve Life Sciences has appointed Dr. Andrew D. Goldberg as its new CEO and Board member, effective after a recent financing. Dr. Goldberg brings a wealth of experience in medicine and business, aiming to enhance operational excellence and shareholder value. The company is focused on advancing cytisinicline, a treatment for nicotine dependence, towards FDA approval.
Read more →ACHV▲ +35.5%on this newsshared move
Achieve Life Sciences Announces Up to $354 Million Private Placement $180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazie
Achieve Life Sciences announced a private placement to raise up to $354 million, which includes $180 million upfront and potential additional funds through warrants. The offering is intended to finance a Phase 3 clinical trial for cytisinicline, a treatment for nicotine dependence, as well as for general corporate purposes. Concurrently, Andrew D. Goldberg will assume the role of CEO following the placement's close. The transaction is scheduled to finalize on April 17, 2026, pending customary closing conditions.
Read more →ACHVAchieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
Achieve Life Sciences has made significant operational progress by completing the technology transfer of cytisinicline manufacturing to Adare Pharma Solutions. The first engineering batch has been successfully produced, positioning the company for future commercial production. However, Achieve faces challenges with an FDA classification indicating compliance issues at a third-party facility, which may affect its regulatory timeline.
Read more →ACHVAchieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability
Achieve Life Sciences announced a publication in Nicotine & Tobacco Research detailing the receptor selectivity of cytisinicline, a treatment for nicotine dependence. The study highlights cytisinicline's strong binding to nicotinic receptors and minimal interaction with the 5-HT3 receptor, which may explain its low nausea rates. This research supports the drug's favorable tolerability and potential effectiveness in smoking cessation.
Read more →ACHVAchieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline’s Receptor Selectivity to Low Nausea Rates and Favorable Tolerability
Achieve Life Sciences announced a publication in Nicotine & Tobacco Research detailing the receptor selectivity of cytisinicline, a treatment for nicotine dependence. The study highlights cytisinicline's strong binding to nicotinic receptors and minimal interaction with serotonin receptors, which may explain its low incidence of nausea. This could enhance its appeal for individuals attempting to quit smoking or vaping.
Read more →ACHV▼ -28.4%on this newsshared move
Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Achieve Life Sciences reported its financial results for Q4 and full year 2025, highlighting a partnership with Adare Pharma Solutions for cytisinicline manufacturing. The company is making strides towards regulatory approval, with a PDUFA date set for June 20, 2026. Achieve aims to launch cytisinicline for nicotine dependence in the first half of 2027, despite facing some manufacturing compliance challenges.
Read more →ACHVAchieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026
Achieve Life Sciences will announce its fourth quarter and full year 2025 financial results on March 24, 2026. The company will provide updates on its cytisinicline development program, which is under FDA review. Cytisinicline aims to treat nicotine dependence, with a PDUFA date set for June 20, 2026.
Read more →ACHV▲ +5.8%on this news
Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study
Achieve Life Sciences presented new data at the SRNT 2026 Annual Meeting, highlighting the effectiveness of cytisinicline in aiding smoking cessation. A pooled analysis of over 1,600 participants demonstrated significant quit rates, even among those with prior unsuccessful attempts. Additionally, survey data from the ORCA-OL study provided insights into participant experiences with extended cytisinicline use.
Read more →ACHVAchieve Life Sciences Announced Granting of New Hire Inducement Awards - January 30, 2026
Achieve Life Sciences has announced the granting of stock options to five new employees as part of its 2024 Equity Inducement Plan. The options, totaling 115,000 shares, will vest over four years, contingent on continued employment. This move aligns with the company's focus on developing cytisinicline for nicotine dependence, which is currently under FDA review.
Read more →ACHVAchieve Life Sciences Announced Granting of New Hire Inducement Awards
Achieve Life Sciences has granted stock options to five new employees as part of its 2024 Equity Inducement Plan. The options, totaling 115,000 shares, will vest over four years, promoting employee retention. This move comes as the company continues to develop cytisinicline, a treatment for nicotine dependence, with an FDA review underway for its New Drug Application.
Read more →ACHVAchieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
Achieve Life Sciences has confirmed the promotion of Dr. Mark Rubinstein to Chief Medical Officer. Since his interim appointment, the company has made notable progress in clinical and regulatory milestones, including advancements in the development of cytisinicline for nicotine dependence. Dr. Rubinstein's extensive experience in nicotine cessation is expected to enhance the company's leadership as it approaches FDA review.
Read more →ACHVAchieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
Achieve Life Sciences will host one-on-one meetings during the J.P. Morgan Healthcare Conference from January 12-15, 2026. CEO Rick Stewart and senior management will discuss the company's late-stage cytisinicline program aimed at nicotine dependence. The FDA has accepted their New Drug Application for review, with a PDUFA date set for June 20, 2026.
Read more →ACHVAchieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Achieve Life Sciences reported its third quarter 2025 financial results and announced the FDA's acceptance of its NDA for cytisinicline, targeting nicotine dependence for smoking cessation. The company has a PDUFA action date set for June 20, 2026. Additionally, cytisinicline received a Commissioner’s National Priority Voucher for vaping cessation, highlighting its potential as a first-in-class treatment. Recent data supports its efficacy in diverse populations, furthering its development.
Read more →ACHVAchieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
Achieve Life Sciences has announced key milestones in the NDA review process for cytisinicline, a treatment for nicotine dependence. The completion of the ORCA-OL trial and submission of a 120-day safety update to the FDA bolster the drug's safety profile. The trial exceeded participant requirements, indicating strong tolerability. The FDA has set a PDUFA date of June 20, 2026, for the NDA.
Read more →ACHVAchieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025
Achieve Life Sciences will announce its third quarter 2025 financial results on November 6, 2025. The company will also provide updates on the cytisinicline development program, which aims to treat nicotine dependence. The FDA has accepted their New Drug Application for cytisinicline, with a PDUFA date set for June 20, 2026.
Read more →ACHV▲ +19%on this news
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
Achieve Life Sciences has appointed Erik Atkisson as Chief Legal Officer, who will manage the company's legal strategy and compliance. With over 25 years of experience in the biopharmaceutical sector, Atkisson's expertise is expected to support Achieve's growth and regulatory efforts for cytisinicline, a treatment for nicotine dependence. The FDA has accepted the company's New Drug Application for review.
Read more →ACHV▲ +36.4%on this news· ran to +66% by day 3shared move
Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation
Achieve Life Sciences has been awarded the FDA Commissioner's National Priority Voucher for cytisinicline, aimed at treating nicotine dependence specifically for e-cigarette and vaping cessation. This designation allows for expedited review, potentially reducing assessment time to one to two months. Cytisinicline has shown clinical efficacy in trials, making it a promising candidate for addressing a significant unmet medical need.
Read more →ACHV▲ +36.4%on this news· ran to +66% by day 3shared move
Achieve Life Sciences Receives FDA Commissioner’s National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation
Achieve Life Sciences has been awarded a Commissioner’s National Priority Voucher by the FDA for its drug cytisinicline, aimed at treating nicotine dependence related to e-cigarettes and vaping. This designation allows for expedited review, potentially reducing assessment time significantly. Cytisinicline has shown clinical efficacy in trials and addresses a critical need for vaping cessation treatments.
Read more →ACHVAchieve Life Sciences Announces Granting of New Hire Inducement Awards
Achieve Life Sciences announced the granting of stock options to five new employees as part of its 2024 Equity Inducement Plan. The options are tied to the company's ongoing efforts to develop cytisinicline for smoking cessation and have a ten-year term with a vesting schedule. The company is also preparing for a PDUFA date set for June 20, 2026, regarding its New Drug Application for cytisinicline.
Read more →ACHVAchieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD
Achieve Life Sciences announced the publication of data in Thorax showing that cytisinicline significantly improves smoking cessation rates in individuals with and without COPD. The study, based on over 1,600 participants from Phase 3 trials, highlights cytisinicline's potential as a well-tolerated treatment option for high-risk COPD patients. The FDA has accepted the New Drug Application for cytisinicline, with a target action date of June 20, 2026.
Read more →ACHVAchieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer
Achieve Life Sciences has promoted Craig Donnelly to Chief Operations Officer. In this role, he will oversee the integration of supply chain and manufacturing operations in preparation for the anticipated launch of cytisinicline, a treatment for nicotine dependence, in mid-late 2026. His extensive experience in the biopharmaceutical industry is expected to support the company's goals for regulatory approval and commercialization.
Read more →ACHVAchieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer
Achieve Life Sciences has appointed Dr. Mark Rubinstein as Interim Chief Medical Officer, succeeding Cindy Jacobs. Dr. Rubinstein brings extensive experience in clinical development and medical affairs, previously holding significant roles at Blip and Juul Labs. The company is advancing its cytisinicline treatment for nicotine dependence, with recent FDA acceptance of its New Drug Application.
Read more →ACHVAchieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation
Achieve Life Sciences announced the FDA's acceptance of its New Drug Application for cytisinicline, aimed at treating nicotine dependence. This decision initiates the review process, with a PDUFA target date set for June 20, 2026. The NDA is supported by data from pivotal Phase 3 trials, indicating significant efficacy in smoking cessation. The company emphasizes the public health need for effective smoking cessation tools.
Read more →ACHVAchieve Life Sciences Announces Participation at Upcoming Investor Conferences
Achieve Life Sciences, Inc. announced that CEO Rick Stewart will participate in two investor conferences in September 2025. The company is focused on the development of cytisinicline for nicotine dependence, having submitted a New Drug Application to the FDA. Cytisinicline aims to address the smoking cessation market, which is critical given the high rates of tobacco-related deaths.
Read more →ACHVAchieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Achieve Life Sciences announced its financial results for Q2 2025, highlighting the submission of a New Drug Application (NDA) for cytisinicline to the FDA. The company has partnered with Omnicom to enhance its commercialization strategy and raised $49.3 million to support ongoing development. The NDA submission is backed by positive results from Phase 3 trials, indicating cytisinicline's potential as a new treatment for nicotine dependence.
Read more →ACHVAchieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program Conference Call Scheduled for 8:30 AM EDT Today
Achieve Life Sciences has reported its second quarter 2025 financial results and significant advancements in its cytisinicline program, including the submission of a New Drug Application (NDA) to the FDA. The company announced a partnership with Omnicom to enhance the commercialization strategy and raised $49.3 million to support further development. Achieve has completed key long-term safety requirements for cytisinicline, which may become the first new pharmacotherapy for nicotine dependence in nearly 20 years, addressing a significant public health need.
Read more →ACHV▼ -5.2%on this news
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference
Achieve Life Sciences will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. CEO Rick Stewart will engage in a fireside chat during the event. The company is focused on the development of cytisinicline for nicotine dependence and has submitted a New Drug Application to the FDA following successful Phase 3 studies.
Read more →ACHVAchieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025
Achieve Life Sciences plans to announce its second quarter 2025 financial results on August 7, 2025. The company will provide updates on its cytisinicline development program, which aims to treat nicotine dependence. Cytisinicline has received Breakthrough Therapy designation from the FDA, highlighting its potential in addressing smoking cessation needs. However, it remains an investigational product pending regulatory approval.
Read more →ACHVAchieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
Achieve Life Sciences has completed a public offering of 15 million shares, raising $45 million to support the development of cytisinicline for nicotine dependence. The offering included common warrants and was facilitated by Citizens Capital Markets and Raymond James. The company aims to use the funds for FDA approval and general corporate purposes.
Read more →ACHV▼ -36.5%on this newsshared move
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
Achieve Life Sciences has announced the pricing of a $45 million underwritten public offering of 15 million shares of common stock, along with accompanying warrants. The proceeds will be used to support the development of cytisinicline, a treatment for nicotine dependence, as it seeks FDA marketing approval. The offering is expected to close by June 30, 2025.
Read more →ACHVAchieve Life Sciences Announces Proposed Underwritten Public Offering
Achieve Life Sciences has announced a proposed underwritten public offering to sell shares of its common stock and warrants. The proceeds will be used to advance cytisinicline, a treatment for nicotine dependence, towards FDA approval. The offering is contingent on market conditions, and the final terms will be disclosed in a prospectus supplement.
Read more →ACHVAchieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
Achieve Life Sciences has partnered with Omnicom to prepare for the U.S. launch of cytisinicline, a potential new treatment for nicotine dependence. This collaboration aims to leverage advanced marketing technologies and data-driven strategies to effectively engage healthcare professionals and patients. Achieve has completed two Phase 3 studies and submitted a new drug application for cytisinicline, which could significantly impact smoking cessation efforts.
Read more →ACHVAchieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
Achieve Life Sciences has submitted a New Drug Application (NDA) to the FDA for cytisinicline, aimed at treating nicotine dependence for smoking cessation in adults. This submission follows successful Phase 3 trials demonstrating significant efficacy and safety. The company emphasizes the urgent need for effective smoking cessation treatments amidst high smoking-related mortality rates.
Read more →ACHV▼ -7.6%on this news· ran to -42% by day 3shared move
Achieve Life Sciences Announces Proposed Underwritten Public Offering SEATTLE, Wash. and VANCOUVER, British Columbia
Achieve Life Sciences announced a proposed underwritten public offering of its common stock aimed at advancing the development of cytisinicline for treating nicotine dependence. The offering includes an option for underwriters to purchase additional shares and is subject to market conditions. Achieve plans to use the proceeds to support the marketing approval process for cytisinicline and for general corporate purposes. The company recently submitted a New Drug Application to the FDA based on successful clinical studies.
Read more →ACHVAchieve Life Sciences to Present at the Jefferies Global Healthcare Conference
Achieve Life Sciences, a late-stage pharmaceutical company, announced its presentation at the Jefferies Global Healthcare Conference on June 4, 2025. The presentation will highlight the development of cytisinicline, a treatment for nicotine dependence. The company has completed two Phase 3 studies and plans to submit a new drug application for smoking cessation soon.
Read more →ACHVAchieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake
Achieve Life Sciences will present new data on cytisinicline at the 2025 ATS International Conference, highlighting its effectiveness in reducing nicotine cravings and intake. The findings from the Phase 3 ORCA-3 study demonstrate significant benefits, even for smokers who do not quit entirely. The company plans to submit a New Drug Application for cytisinicline in June 2025.
Read more →ACHV▲ +6.9%on this news· ran to +24% by day 3
Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program
Achieve Life Sciences reported its first quarter 2025 financial results, confirming plans to submit a New Drug Application for cytisinicline to the FDA in June 2025. The company highlighted positive results from the Phase 3 ORCA-3 trial published in JAMA Internal Medicine, demonstrating cytisinicline's efficacy in smoking cessation. Additionally, the ORCA-OL trial met FDA long-term exposure requirements without safety issues, further supporting the drug's potential impact on public health.
Read more →ACHV▲ +6.9%on this news· ran to +24% by day 3shared move
Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference
Achieve Life Sciences announced its first quarter 2025 financial results and confirmed plans to submit a New Drug Application for cytisinicline to the FDA by June 2025. The company reported positive findings from the Phase 3 ORCA-3 trial, which were published in JAMA Internal Medicine, demonstrating the drug's efficacy for smoking cessation. Achieve has met safety requirements for long-term use of cytisinicline in its ongoing ORCA-OL trial, with no safety concerns reported. A conference call was scheduled to discuss these developments further.
Read more →ACHV▼ -6.2%on this news
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
Achieve Life Sciences will announce its first quarter 2025 financial results on May 13, 2025. The company will also provide updates on its cytisinicline development program, which aims to treat nicotine dependence. Cytisinicline has completed two Phase 3 studies and has received Breakthrough Therapy designation from the FDA. A conference call will be accessible via a live webcast and phone.
Read more →ACHV▲ +11.3%on this news· ran to +23% by day 1
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
Achieve Life Sciences announced the publication of the ORCA-3 trial results in JAMA Internal Medicine, demonstrating that cytisinicline significantly aids smoking cessation by reducing cravings and increasing quitting rates. The trial involved 792 adults and confirmed the drug's efficacy and tolerability. A New Drug Application to the FDA is planned for June 2025.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
Achieve Life Sciences has reported its financial results for Q4 and year-end 2024, highlighting significant progress in its Cytisinicline development program. The company confirmed the completion of enrollment in the ORCA-OL trial and positive DSMC reviews. Additionally, it announced plans for an NDA submission by the end of Q2 2025 and new leadership appointments.
Read more →ACHVAchieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
Achieve Life Sciences will present at the Barclays 27th Annual Global Healthcare Conference on March 12, 2025. The company focuses on developing cytisinicline for smoking cessation and has completed significant clinical trials. A new drug application for cytisinicline is planned for submission in Q2 2025.
Read more →ACHVAchieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025
Achieve Life Sciences will announce its fourth quarter and year-end 2024 financial results on March 11, 2025. The company will provide updates on its cytisinicline development program, which has completed two Phase 3 studies for smoking cessation. Cytisinicline has received Breakthrough Therapy designation, but the company faces risks regarding regulatory approval and financing.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2
Achieve Life Sciences has reported its financial results for the fourth quarter and year-end 2024, confirming that it is on schedule to submit its NDA for cytisinicline by the end of the second quarter of 2025. Key advancements include the completion of enrollment in the ORCA-OL clinical trial and positive reviews from data safety monitoring committees. The company has strengthened its leadership team with several appointments aimed at bolstering its strategic initiatives. Achieve is positioned to significantly impact public health with a new treatment for nicotine dependence amid escalating concerns over smoking and vaping.
Read more →ACHVAchieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference
Achieve Life Sciences announced that CEO Rick Stewart will present at the Oppenheimer Healthcare Life Sciences Conference. The company is focused on developing cytisinicline for smoking cessation and nicotine dependence, having completed two Phase 3 studies. Achieve plans to submit a new drug application for cytisinicline in Q2 2025, with Breakthrough Therapy designation from the FDA.
Read more →ACHV▲ +5.5%on this newsshared move
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial
Achieve Life Sciences announced a positive review from the Data Safety Monitoring Committee for its ORCA-OL clinical trial of cytisinicline, indicating no unexpected adverse events. The trial, aimed at evaluating long-term safety, continues to show excellent participant adherence. Achieve is on track to file a New Drug Application for cytisinicline in the upcoming quarter.
Read more →ACHV▲ +15.7%on this newsshared move
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reit
Achieve Life Sciences reported a positive outcome from the Data Safety Monitoring Committee's second review of the ORCA-OL clinical trial, indicating no safety concerns for its cytisinicline treatment for smoking cessation. This follows the successful enrollment of 479 participants and previously positive findings from Phase 2 and Phase 3 trials. With strong adherence to the treatment observed among participants, Achieve plans to submit a New Drug Application (NDA) in Q2 2025, aiming to provide a novel prescription treatment for nicotine dependence. The ongoing trial continues to meet FDA safety data requirements for future approval.
Read more →ACHVAchieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors
Achieve Life Sciences has appointed Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors, enhancing its leadership ahead of the NDA submission for cytisinicline. Dr. Slaoui brings extensive experience in corporate development and product commercialization, while Ms. Phelan has a strong background in digital transformation in biopharma. The company continues to focus on combating nicotine dependence.
Read more →ACHV▲ +5.1%on this newsshared move
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
Achieve Life Sciences announced a significant milestone in its ORCA-OL clinical trial, achieving the goal of 300 participants completing six months of treatment with cytisinicline. This data is crucial for the company's planned NDA submission to the FDA, expected in Q2 2025. The ongoing trial has shown no safety concerns, supporting the drug's potential as a new smoking cessation treatment.
Read more →ACHVAchieve Life Sciences Appoints Mark Oki as Chief Financial Officer
Achieve Life Sciences has appointed Mark Oki as Chief Financial Officer, effective December 5, 2024. Oki brings over 25 years of financial leadership experience in the biopharma sector and will oversee the company's financial strategies as it advances cytisinicline, a potential new treatment for nicotine dependence. His expertise is expected to enhance Achieve's efforts in commercialization and financial growth.
Read more →ACHVAchieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA
Achieve Life Sciences announced a successful End-of-Phase 2 meeting with the FDA regarding cytisinicline, a potential treatment for vaping cessation. The FDA approved the proposed Phase 3 study design, allowing Achieve to advance its clinical trials. The upcoming ORCA-V2 trial aims to assess the efficacy and safety of cytisinicline in adults dependent on nicotine e-cigarettes. This development marks a significant step toward addressing the public health challenge of vaping addiction.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Achieve Life Sciences reported its financial results for Q3 2024, highlighting significant advancements in its cytisinicline development program. The company completed enrollment in the Phase 3 ORCA-OL trial and received Breakthrough Therapy designation from the FDA for vaping cessation. Leadership changes were announced to enhance strategic growth, and the company remains on track for an NDA submission in Q2 2025.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Third Quarter 2024 and Provides Corporate Update Company to host conference call at 4:30 PM EST today, Thursday
Achieve Life Sciences reported its financial results for Q3 2024, highlighting significant progress in its cytisinicline development program. The company successfully completed enrollment in the Phase 3 ORCA-OL clinical trial and received Breakthrough Therapy designation from the FDA for the treatment of nicotine dependence, specifically for vaping cessation. Additionally, Achieve announced changes in its executive leadership team to enhance its growth strategy. The company remains on track for a New Drug Application submission in the second quarter of 2025, aimed at addressing the urgent need for smoking cessation solutions.
Read more →ACHVAchieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 7, 2024
Achieve Life Sciences will announce its third quarter 2024 financial results on November 7, 2024, and provide updates on its cytisinicline development program. The company aims to address nicotine dependence, with cytisinicline being a key investigational product. The announcement reflects Achieve's commitment to tackling nicotine addiction.
Read more →ACHVAchieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting
Dr. Cindy Jacobs, President and CMO of Achieve Life Sciences, presented at a recent FDA and NIH public meeting focused on smoking cessation. She highlighted the advancements of cytisinicline, a treatment for nicotine dependence, which has shown promising results in Phase 3 trials. The meeting aimed to accelerate innovation in smoking cessation therapies, addressing a critical public health issue.
Read more →ACHVAchieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline
Achieve Life Sciences has promoted Jaime Xinos to Chief Commercial Officer to lead the commercial operations for cytisinicline, an investigational treatment for nicotine dependence. Xinos, who has been with the company since 2017, will focus on strategic partnerships and market readiness ahead of the anticipated FDA approval. Her extensive experience in the biotech industry positions her to drive the company's commercial initiatives effectively.
Read more →ACHVAchieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting
Achieve Life Sciences has completed enrollment in its ORCA-OL clinical trial, involving 479 participants across 29 sites. The trial evaluates the long-term effects of cytisinicline for nicotine dependence. The Data Safety Monitoring Committee reported no safety concerns, allowing the trial to proceed as planned. Achieve aims to file for NDA in early 2025.
Read more →ACHVAchieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs
Achieve Life Sciences has appointed Dr. Mark L. Rubinstein as the new Head of Medical Affairs. With over two decades of experience in nicotine dependence and smoking cessation, Dr. Rubinstein is expected to play a crucial role in advancing Achieve's initiatives. His leadership comes at a pivotal time as the company approaches FDA approval for cytisinicline, a potential breakthrough treatment for nicotine addiction.
Read more →ACHVAchieve Life Sciences Announces Changes in Executive Leadership and Board of Directors
Achieve Life Sciences has announced a leadership change, with co-founder Rick Stewart returning as CEO and Thomas King becoming Executive Chairman. The transition aims to leverage Stewart's experience in M&A and commercialization to drive the cytisinicline program forward. The company remains focused on completing key studies and preparing for regulatory submissions.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
Achieve Life Sciences reported its Q2 2024 financial results, highlighting significant milestones including FDA Breakthrough Therapy designation for cytisinicline aimed at vaping cessation. The company also refinanced its loans and initiated the ORCA-OL trial to assess long-term effects of cytisinicline. Despite a reported net loss, Achieve's inclusion in major stock indexes reflects its strong market potential.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today, Tuesday
Achieve Life Sciences, Inc. announced its second-quarter 2024 financial results and significant progress in its cytisinicline development for nicotine cessation. The FDA granted Breakthrough Therapy designation for the treatment, expediting its regulatory review. Achieve has also refinanced its loans, ensuring financial stability while enhancing its visibility through inclusion in the Russell 3000 and Russell Microcap Indexes. However, the company reported a net loss of $8.5 million during the quarter, highlighting ongoing financial challenges.
Read more →ACHVAchieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence
Achieve Life Sciences announced that the FDA has granted Breakthrough Therapy Designation for cytisinicline, aimed at treating nicotine dependence from e-cigarettes and vaping. This designation could expedite the drug's development, potentially making it the first approved pharmacotherapy for vaping cessation. The Phase 2 ORCA-V1 trial showed promising results, with participants using cytisinicline being significantly more likely to quit vaping compared to those on placebo.
Read more →ACHVAchieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank
Achieve Life Sciences has announced a $20 million refinancing agreement with Silicon Valley Bank, extending the maturity date of its existing debt to December 1, 2027. This refinancing is expected to lower the company's cost of capital and extend its cash runway as it advances its investigational drug, cytisinicline, through the FDA approval process. The loan is structured in three tranches, with specific conditions for additional funding based on regulatory milestones.
Read more →ACHVAchieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024
Achieve Life Sciences will announce its second quarter 2024 financial results on August 13, 2024, and provide updates on its cytisinicline development program. Cytisinicline aims to aid smoking cessation and nicotine dependence, targeting a significant health crisis. The company emphasizes the importance of this treatment amid rising e-cigarette use and smoking-related health issues.
Read more →ACHVAchieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
Achieve Life Sciences will present at the JonesHealthcare Seaside Summit 2024, focusing on cytisinicline for smoking cessation. CEO John Bencich will speak on July 15, 2024, and participate in a panel discussion. The company aims to combat nicotine addiction, with cytisinicline being a key investigational product. However, it has not yet received FDA approval.
Read more →ACHVAchieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes
Achieve Life Sciences has announced its addition to the U.S. Russell 3000 and Russell Microcap Indexes, effective July 1, 2024. This inclusion is seen as a significant opportunity to increase investor visibility. The company is also preparing for a new drug application for cytisinicline, aimed at smoking cessation, expected in the first half of 2025. However, there are risks associated with the non-binding refinancing agreement and the regulatory approval process.
Read more →ACHVAchieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has begun screening subjects for the ORCA-OL clinical trial, which aims to gather long-term safety data on cytisinicline for smoking cessation. This trial is essential for the New Drug Application (NDA) submission to the FDA. With a focus on prior trial participants, the study aims to enroll swiftly and provide critical safety data for potential approval in 2025.
Read more →ACHVAchieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
Achieve Life Sciences announced that data from its Phase 2 ORCA-V1 trial on cytisinicline for vaping cessation will be presented at the SGIM Annual Meeting. The trial showed that treatment with cytisinicline significantly increased the likelihood of quitting e-cigarettes compared to a placebo. The findings are expected to contribute to the understanding of nicotine dependence and smoking cessation strategies.
Read more →ACHVAchieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Achieve Life Sciences reported its financial results for Q1 2024, highlighting significant progress in the development of cytisinicline for smoking cessation. The company published positive results from the Phase 2 ORCA-V1 trial and plans to initiate the ORCA-OL trial soon. Additionally, Achieve secured $124.2 million in equity financing to support ongoing clinical development and preparations for a New Drug Application submission.
Read more →ACHVAchieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today, Thursday
Achieve Life Sciences announced its financial results for Q1 2024, highlighting advancements in the development of cytisinicline for smoking cessation. Key developments include positive Phase 2 trial results published in JAMA Internal Medicine and plans to initiate a long-term safety trial (ORCA-OL) in May 2024. The company secured up to $124.2 million in financing, which will support ongoing clinical research and operational costs. Despite facing a net loss during the quarter, Achieve remains optimistic about its future prospects in addressing nicotine dependence.
Read more →ACHVAchieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
Achieve Life Sciences announced the publication of ORCA-V1 trial results in JAMA Internal Medicine, demonstrating cytisinicline's efficacy in aiding vaping cessation. The trial showed that 31.8% of participants using cytisinicline achieved abstinence compared to 15.1% on placebo. The treatment was well tolerated, with no serious adverse events reported, and Achieve plans to meet with the FDA regarding future clinical trials.
Read more →ACHVAchieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024
Achieve Life Sciences will announce its first quarter 2024 financial results on May 9, 2024, and provide updates on its cytisinicline development program. Cytisinicline is a plant-based treatment aimed at nicotine addiction, currently not FDA-approved. The company emphasizes the importance of addressing the smoking epidemic, which remains a significant public health issue.
Read more →ACHVAchieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference
Achieve Life Sciences will present at the Life Science Innovation Northwest 2024 Conference, focusing on cytisinicline, a treatment for smoking cessation. CEO John Bencich's presentation is scheduled for April 18, 2024. The company aims to combat nicotine addiction, which affects millions globally. However, cytisinicline remains investigational and lacks FDA approval.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
Achieve Life Sciences announced its fourth quarter and year-end 2023 financial results, highlighting significant milestones in the development of cytisinicline for smoking cessation. The company secured an agreement with the FDA regarding NDA submission requirements and completed a substantial equity financing. Positive trial data was presented at a recent conference, indicating the potential efficacy of cytisinicline.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today, Thursday
Achieve Life Sciences has announced its financial results for the fourth quarter and year-end 2023, highlighting key milestones in the development of cytisinicline for smoking cessation. The company reported an agreement with the FDA regarding long-term study requirements for a New Drug Application, along with completion of significant equity financing. Clinical trial results presented showed promising efficacy and safety for cytisinicline. Despite these advancements, the company reported a substantial net loss, raising concerns about future funding and the need for FDA approval before commercialization.
Read more →ACHVAchieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
Achieve Life Sciences announced that data from its Phase 3 ORCA-2 and ORCA-3 trials, along with the Phase 2 ORCA-V1 trial, will be presented at the 2024 SRNT Annual Meeting. The trials evaluate cytisinicline's efficacy for smoking and vaping cessation. Results indicate increased abstinence rates and good tolerability. The presentations highlight the potential of cytisinicline as a new treatment option for nicotine dependence.
Read more →ACHVAchieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024
Achieve Life Sciences will announce its fourth quarter and year-end 2023 financial results on March 28, 2024. The company will also provide updates on its cytisinicline development program, aimed at treating nicotine addiction. Cytisinicline is a plant-based alkaloid that interacts with nicotine receptors to help reduce withdrawal symptoms. The webcast and conference call will be accessible to the public.
Read more →ACHV▼ -9.2%on this news
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
Achieve Life Sciences has secured an agreement with the FDA regarding the long-term exposure data needed for its New Drug Application (NDA) for cytisinicline, a treatment for smoking cessation. The FDA supports the efficacy data from two completed Phase 3 trials and requires additional long-term safety data. Achieve plans to initiate an open-label trial to gather this data, with NDA submission anticipated in the first half of 2025. The company is also well-funded to proceed with its clinical development plans.
Read more →ACHV▼ -9.2%on this newsshared move
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
Achieve Life Sciences has announced a registered direct offering and concurrent private placement aimed at raising up to $124.2 million. This funding will primarily support the clinical development of cytisinicline, a treatment for nicotine dependence. The offering is expected to close around March 4, 2024, and includes participation from various strategic investors.
Read more →ACHV▼ -9.2%on this newsshared move
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement $60 million financing upfront with up to an additional $64.2 million tied to exercise of milesto
Achieve Life Sciences announced a financing deal to raise up to $124.2 million through a registered direct offering and concurrent private placement. The initial $60 million will be used to further the clinical development of cytisinicline, a product aimed at treating nicotine dependence, with the expectation of submitting a New Drug Application in the first half of 2025. Additional funds up to $64.2 million could be raised through milestone-driven warrants. The offering is expected to close around March 4, 2024, subject to customary conditions.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update
Achieve Life Sciences reported its third quarter 2023 financial results and provided updates on its cytisinicline development program. The company highlighted positive outcomes from the Phase 3 ORCA-2 trial and Phase 2 ORCA-V1 results, demonstrating the efficacy of cytisinicline for smoking cessation. Achieve aims to meet FDA requirements for a New Drug Application while managing ongoing clinical studies and financial challenges.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update Company to host conference call at 4:30 PM EST today, Thursday
Achieve Life Sciences, a late-stage pharmaceutical company, reported its third quarter financial results and provided an update on its cytisinicline development program. The company highlighted significant achievements, including the publication of Phase 3 ORCA-2 trial results in a medical journal and positive outcomes from its Phase 2 ORCA-V1 study. Achieve announced that it has completed dosing for key clinical trials supporting its New Drug Application for cytisinicline, which targets smoking cessation and nicotine dependence. With a cash reserve of $20 million as of September 30, the company plans to discuss these developments in an upcoming conference call.
Read more →ACHVAchieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023
Achieve Life Sciences will announce its third quarter 2023 financial results on November 9, 2023. The company will also provide updates on its cytisinicline development program, aimed at addressing nicotine addiction. Cytisinicline is an investigational treatment that has not yet received FDA approval. The announcement reflects Achieve's commitment to transparency and investor communication.
Read more →ACHVAchieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
Achieve Life Sciences announced the presentation of positive results from the Phase 2 ORCA-V1 trial at the SRNT-E Annual Meeting. The trial evaluated cytisinicline for e-cigarette cessation, showing 2.6 times higher odds of cessation compared to placebo. The treatment was well tolerated, with only minor side effects reported.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update Company to host conference call tomorrow, Tuesday
Achieve Life Sciences reported its financial results for Q2 2023 and announced significant advancements in its cytisinicline program. Notable developments include the positive results from the Phase 3 ORCA-2 and ORCA-3 trials for smoking cessation, as well as the Phase 2 ORCA-V1 trial for vaping cessation. The company raised approximately $16.5 million through an equity financing and refinanced its loan with Silicon Valley Bank. Achieve aims to file a New Drug Application for cytisinicline in the first half of 2024, targeting the smoking cessation market.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Sec Quarter 2023 and Provides Corporate Update
Achieve Life Sciences reported its financial results for Q2 2023, highlighting positive outcomes from its Phase 3 ORCA-2 and ORCA-3 trials for cytisinicline, aimed at smoking cessation. The company raised approximately $16.5 million through equity financing and refinanced its loan with Silicon Valley Bank. Achieve plans to submit a New Drug Application for cytisinicline in early 2024.
Read more →ACHVAchieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast
Achieve Life Sciences will announce its second quarter 2023 financial results on August 14, 2023, followed by a conference call on August 15, 2023. The company is developing cytisinicline, a potential treatment for smoking cessation and nicotine dependence. Despite its promise, cytisinicline remains investigational and has not received FDA approval.
Read more →ACHVAchieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting
Achieve Life Sciences announced its participation in the 2023 American Society of Pharmacognosy Annual Meeting, where CEO John Bencich and Executive Chairman Richard Stewart will discuss public/private partnerships. The meeting will take place from July 22-26, 2023, in Rockville, MD. The company aims to address nicotine addiction through its investigational product, cytisinicline.
Read more →ACHVAchieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in <em>Journal of the American Medical Association (JAMA)</em>
Achieve Life Sciences announced the publication of positive results from the Phase 3 ORCA-2 trial of cytisinicline for smoking cessation in JAMA. The trial demonstrated significantly higher abstinence rates compared to placebo, with excellent tolerability. Achieve plans to submit a New Drug Application to the FDA for cytisinicline in 2024, potentially marking a significant advancement in smoking cessation treatments.
Read more →ACHV▼ -6.1%on this news
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering SEATTLE, Wash. and VANCOUVER, British Columbia
Achieve Life Sciences, a pharmaceutical company focused on nicotine dependence treatments, announced the pricing of a registered direct offering to raise $16.5 million. The company will sell 3 million shares at $5.50 each, with proceeds intended for product development and working capital. This offering is expected to close around May 30, 2023, pending customary closing conditions. The transaction includes participation from existing investors, indicating their continued support for Achieve's efforts in addressing nicotine addiction through its product cytisinicline.
Read more →ACHV▼ -23.8%on this newsshared move
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial ORCA-3 demonstrated statistically significant topline results in primary
Achieve Life Sciences announced positive topline results from its Phase 3 ORCA-3 trial for cytisinicline, showing significant benefits in smoking cessation compared to a placebo. The trial involved 792 adult smokers, demonstrating increased odds of quitting smoking with both 6 and 12-week treatment durations. Cytisinicline was well-tolerated, presenting low rates of adverse events. The results suggest that this treatment could be an effective option for those struggling with nicotine dependence, potentially becoming the first new prescription aid in two decades.
Read more →ACHVAchieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today
Achieve Life Sciences announced positive first quarter 2023 financial results and updates concerning the development of cytisinicline, an investigational treatment for smoking cessation. The company highlighted encouraging results from the Phase 2 ORCA-V1 trial, which demonstrated significant vaping cessation benefits for participants treated with cytisinicline. Additionally, Achieve confirmed the completion of key milestones in the Phase 3 ORCA-3 trial and presented favorable analyses at a recent nicotine research meeting. The company continues to aim for regulatory approval of cytisinicline, which could become the first new treatment for smoking cessation since 2003.
Read more →ACHV▲ +5.9%on this news
Achieve Life Sciences Announces Refresh to Board of Directors SEATTLE, Wash. and VANCOUVER, British Columbia
Achieve Life Sciences announced a refreshment of its Board of Directors as part of its strategy to enhance the company's future direction. Three new members, including Stuart Duty, Thomas King, and Tom Sellig, have been appointed, while three existing members will not be nominated for re-election. The changes aim to support the ongoing development of cytisinicline, a potential treatment for smoking cessation and nicotine dependence, as the company prepares for its Annual Meeting of Stockholders in June 2023.
Read more →ACHVAchieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update Company to host conference call
Achieve Life Sciences announced its financial results for the fourth quarter and year-end 2022, highlighting a net loss of $11.2 million for Q4 and $42.4 million for the year. The company raised $18.9 million through a private placement to fund ongoing clinical trials for its smoking cessation drug, cytisinicline. Promising results from the Phase 3 ORCA-2 trial were presented at a recent conference, supporting the drug's potential efficacy. Achieve anticipates 2023 to be a pivotal year, with topline results expected from multiple ongoing trials.
Read more →ACHV▲ +5.5%on this news
Achieve Life Sciences Announces Private Placement of $18.9 Million SEATTLE, Wash. and VANCOUVER, British Columbia
Achieve Life Sciences Announces Private Placement of $18.9 Million SEATTLE, Wash. and VANCOUVER, British Columbia, November 15, 2022 -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercializat
Read more →ACHVAchieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update Company to host conference call at 4:30 PM EST today
Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update Company to host conference call at 4:30 PM EST today, November 14, 2022 SEATTLE, WA and VANCOUVER, British Columbia, November 14, 2022 (GLOBE NEWSWIRE) - Achieve Life Sciences, Inc. (NASDAQ:
Read more →ACHVAchieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today
Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today, August 11, 2022 SEATTLE, Wash and VANCOUVER, British Columbia, August 11, 2022 - Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stag
Read more →ACHVAchieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today
Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today, May 12, 2022 SEATTLE, Wash and VANCOUVER, British Columbia, May 12, 2022 - Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage p
Read more →ACHV▲ +7.7%on this news
Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers Clinically robust and statistically significant results i
Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers Clinically robust and statistically significant results in primary and secondary endpoints for both 6- and 12-week c
Read more →ACHVAchieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update Company to host conference call at 4:30 PM EST today
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update Company to host conference call at 4:30 PM EST today, March 10, 2022 SEATTLE, Wash and VANCOUVER, British Columbia, March 10, 2022 - Achieve Life Sciences, Inc. (N
Read more →ACHVAchieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development SEATTLE, Wash and VANCOUVER, British Columbia, November 9, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the globa
Read more →ACHVAchieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update SEATTLE, Wash and VANCOUVER, British Columbia, August 12, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and c
Read more →ACHVAchieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update SEATTLE, Wash and VANCOUVER, British Columbia, May 13, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and comme
Read more →ACHVAchieve Life Sciences Announces Appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Board of Directors SEATTLE, Wash. and VANCOUVER, British Columbia
Achieve Life Sciences Announces Appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Board of Directors SEATTLE, Wash. and VANCOUVER, British Columbia, March 15, 2021 - Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the glo
Read more →ACHVAchieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update SEATTLE, Wash and VANCOUVER, British Columbia, March 11, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global devel
Read more →ACHVAchieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update SEATTLE, Wash and VANCOUVER, British Columbia, November 12, 2020 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed
Read more →ACHVAchieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program SEATTLE, Wash and VANCOUVER, British Columbia, August 6, 2020 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to th
Read more →ACHVAchieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering SEATTLE, Wash. and VANCOUVER, British Columbia
Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering SEATTLE, Wash. and VANCOUVER, British Columbia, June 29, 2020 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercia
Read more →ACHVAchieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program SEATTLE, Wash and VANCOUVER, British Columbia, May 14, 2020 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the g
Read more →ACHVAchieve Life Sciences Announces Private Placement of $1.9 Million SEATTLE, Wash. and VANCOUVER, British Columbia
Achieve Life Sciences Announces Private Placement of $1.9 Million SEATTLE, Wash. and VANCOUVER, British Columbia, April 30, 2020 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cy
Read more →ACHVAchieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program SEATTLE, Wash and VANCOUVER, British Columbia, March 13, 2020 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company co
Read more →ACHVAchieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering SEATTLE, Wash. and VANCOUVER, British Columbia
Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering SEATTLE, Wash. and VANCOUVER, British Columbia, December 17, 2019 - Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and com
Read more →ACHVAchieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program SEATTLE, Wash and VANCOUVER, British Columbia, November 6, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to t
Read more →ACHVBackground (-)-Cytisine is a naturally-occurring substance extracted from Cytisus laburnum (Golden chain) USAN (U.S. Approved Name) is cytisinicline Available in Central & Eastern Europe for many years Traditional dosing
A multicenter, double-blind, randomized, placebo-controlled phase 2b trial of cytisinicline in adult smokers Nides M.1, Rigotti N.2, Benowitz N.3, Cain D.4, Clarke A.4, Jacobs C.4 1 Los Angeles Clinical Trials, Burbank, United States 2 Massachusetts General Hospital/Harvard Med
Read more →ACHVAchieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia, August 8, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the
Read more →ACHVAchieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial 3.0 mg, 3 times daily selected as dose for future c
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial 3.0 mg, 3 times daily selected as dose for future clinical development SEATTLE, Wash. and VANCOUVER, Britis
Read more →ACHVAchieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia, May 15, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the glo
Read more →ACHVAchieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia, March 14, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global
Read more →ACHVAchieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia, November 7, 2018 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company commi
Read more →ACHVAchieve Announces Pricing of $5.6 Million Registered Direct Offering SEATTLE, Wash. and VANCOUVER, British Columbia
Achieve Announces Pricing of $5.6 Million Registered Direct Offering SEATTLE, Wash. and VANCOUVER, British Columbia, October 1, 2018 Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of
Read more →ACHVAchieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed and Fasted Subjects SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed SEATTLE, Wash and VANCOUVER, British Columbia, Sept. 27, 2018 Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to
Read more →ACHVAchieve Reports Financial Results for Second Quarter 2018 and Provides Cytisine Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for Second Quarter 2018 and Provides Cytisine Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia, August 8, 2018 -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the globa
Read more →ACHVAchieve Life Sciences, Inc. Announces Reverse Stock Split SEATTLE, Wash. and VANCOUVER, British Columbia
Achieve Life Sciences, Inc. Announces Reverse Stock Split SEATTLE, Wash. and VANCOUVER, British Columbia, May 23, 2018 Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for s
Read more →ACHVAchieve Reports Financial Results for First Quarter 2018 SEATTLE, Wash and VANCOUVER, British Columbia
Achieve Reports Financial Results for First Quarter 2018 SEATTLE, Wash and VANCOUVER, British Columbia, May 9, 2018 -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for sm
Read more →ACHVAchieve Announces Recent Highlights and Reports Year-End 2017 Financial Results BOTHELL, Wash and VANCOUVER, British Columbia
Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results BOTHELL, Wash and VANCOUVER, British Columbia, March 1, 2018 -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commerciali
Read more →ACHVAchieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study BOTHELL, Washington and VANCOUVER, British Columbia
Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study BOTHELL, Washington and VANCOUVER, British Columbia, February 20, 2018 Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutica
Read more →ACHVAchieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories BOTHELL,
BOTHELL, Washington and VANCOUVER, British Columbia, January 24, 2018 Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an amendment to
Read more →ACHVConsolidated Statements of Loss (In thousands, except per share and share data) (unaudited) Three months ended September 30, Twelve months ended
Achieve Reports Financial Results for Third Quarter 2017 BOTHELL, Wash and VANCOUVER, British Columbia, November 9, 2017 -Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for
Read more →ACHVAchieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC BOTHELL, Wash and VANCOUVER, British Columbia
Achieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC BOTHELL, Wash and VANCOUVER, British Columbia, Sept. 14, 2017 Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercializ
Read more →ACHVAchieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation Treatment Strategic Collaboration with the National Institutes of Health (NIH) Instrumental in Facili
Strategic Collaboration with the National Institutes of Health (NIH) Instrumental in Facilitating IND-enabling Studies BOTHELL, Wash and VANCOUVER, British Columbia, Aug. 10, 2017 Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced that the U.S. Food and Drug Administrat
Read more →ACHVAchieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC Special Meeting of OncoGenex Stockholders to Vote on Proposed Merger Scheduled for
Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC Special Meeting of OncoGenex Stockholders to Vote on Proposed Merger Scheduled for August 1, 2017 MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2017 BOTHELL, WA, and VANCOUVER, British Columbia
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2017 BOTHELL, WA, and VANCOUVER, British Columbia, May 15, 2017 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced financial results for the first quarter ended March 31, 2017. of March 31,
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016 BOTHELL, WA, and VANCOUVER, British Columbia
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016 BOTHELL, WA, and VANCOUVER, British Columbia, Feb. 23, 2017 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its year end 2016 As of December 31, 2016, the company s cash, cash equivalent
Read more →ACHVThis presentation contains forward looking statements, including, but not limited to, statements regarding the terms, timing, conditions to and anticipated completion of the proposed merger; the expected ownership of the
Meet with EMA to agree on EU regulatory pathway Meet with national regulators in Germany, Holland Sweden Determine whether existing MAA dossier is sufficient for MAA submission Include new non clinical data Include data from TASC and CASCAID Phase 3 trials Potential to file an MA
Read more →ACHVOncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement Proposed Merger Will Create Clinical-Stage, Biopharmaceutical Company Focused on the Development and Commercialization o
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement Proposed Merger Will Create Clinical-Stage, Biopharmaceutical Company Focused on the Development and Commercialization of Cytisine for Smoking Cessation Multiple Clinical and R
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2016 BOTHELL, WA, and VANCOUVER, British Columbia
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2016 BOTHELL, WA, and VANCOUVER, British Columbia, Nov. 10, 2016 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its third quarter 2016 financial results. As of September 30, 2016, the
Read more →ACHVOncoGenex Announces Positive Survival Results from Apatorsen Phase 2 Borealis-2 Trial in Metastatic Bladder Cancer Randomized Trial of 200 Patients Meets Primary Endpoint of Overall Survival BOTHELL, Wash. and VANCOUVER,
OncoGenex Announces Positive Survival Results from Apatorsen Phase 2 Borealis-2 Trial in Metastatic Bladder Cancer Randomized Trial of 200 Patients Meets Primary Endpoint of Overall Survival BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 25, 2016 OncoGenex Pharmaceutical
Read more →ACHVOncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer Company to Host Conference Call Today, Thursday
OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer Company to Host Conference Call Today, Thursday, October 13, 2016 at 8:00 a.m. EDT BOTHELL Wash. And VANCOUVER, British Columbia, Oct. 13, 2016 OncoGenex Pharmaceuticals, Inc.
Read more →ACHVOncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer Conference Call on Tuesday
OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer Conference Call on Tuesday, August 16, 2016 at 7:30 a.m. EDT BOTHELL Wash. And VANCOUVER, British Columbia, August 16, 2016 OncoGenex Pharmaceutic
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016 Pivotal Phase 3 Prostate Trial Results Expected in Third Quarter 2016 BOTHELL, WA, and VANCOUVER, British Columbia
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016 Pivotal Phase 3 Prostate Trial Results Expected in Third Quarter 2016 BOTHELL, WA, and VANCOUVER, British Columbia, Aug. 4, 2016 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced it
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016 Anticipated 2016 Milestones Include Data from Phase 3 Prostate, Phase 2 Bladder, and Phase 2 Lung Cancer Trials BOTHELL, WA, and VANCOUVER,
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016 Anticipated 2016 Milestones Include Data from Phase 3 Prostate, Phase 2 Bladder, and Phase 2 Lung Cancer Trials BOTHELL, WA, and VANCOUVER, British Columbia, May 12, 2016 - OncoGenex Pharmaceutica
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2015 Conference call to be held on Wed.
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2015 Conference call to be held on Wed., March 9, 2016 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, March 9, 2016 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced y
Read more →ACHVOncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities BOTHELL Wash. And VANCOUVER, British Columbia
OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities BOTHELL Wash. And VANCOUVER, British Columbia, February 4, 2016 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it is implementing a plan
Read more →ACHVOncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer BOTHELL Wash. And VANCOUVER, British Columbia
OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer BOTHELL Wash. And VANCOUVER, British Columbia, January 20, 2016 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from the Phase 2 Spruce tri
Read more →ACHVOncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses Final Results Expected in Second Half of 2016 BOTHELL Wash. and VANCOUVER, British Columbia
OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses Final Results Expected in Second Half of 2016 BOTHELL Wash. and VANCOUVER, British Columbia, December 1, 2015 Following an independent Data Monitoring Committee (DMC) meeting, OncoGen
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2015 Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2015 Conference call to be held on Thursday, November 12, 2015 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, November 12, 2015 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI)
Read more →ACHVOncoGenex Announces Phase 2 Rainier Results in Previously Untreated Metastatic Pancreatic Cancer BOTHELL, Wash. and VANCOUVER, British Columbia
OncoGenex Announces Phase 2 Rainier Results in Previously Untreated Metastatic VANCOUVER, British Columbia, Sept. 23, 2015 /CNW/ OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2015 Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2015 Conference call to be held on Thursday, August 13, 2015 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, August 13, 2015 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) tod
Read more →ACHVOncoGenex Announces Custirsen Phase 3 ENSPIRIT Trial Continues Following Completion of Final Futility Survival Analysis Rigorous Criteria Met, Trial in NSCLC Patients Proceeds as Planned BOTHELL, Wash. and VANCOUVER, Bri
OncoGenex Announces Custirsen Phase 3 ENSPIRIT Trial Continues Following Completion of Final Futility Survival Analysis Rigorous Criteria Met, Trial in NSCLC Patients Proceeds as Planned BOTHELL, Wash. and VANCOUVER, British Columbia, July 13, 2015 /CNW/ OncoGenex Pharmaceutic
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2015 Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2015 Conference call to be held on Thursday, May 14, 2015 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, May 14, 2015 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announ
Read more →ACHVOncoGenex Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC Funds to Help Further Development of Recently Re-acquired Custirsen Program BOTHELL Wash. and VANCOUVER, British Columbia
OncoGenex Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC Funds to Help Further Development of Recently Re-acquired Custirsen Program BOTHELL Wash. and VANCOUVER, British Columbia, April 30, 2015 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announ
Read more →ACHVOncoGenex Regains Rights to Custirsen from Teva BOTHELL Wash. and VANCOUVER, British Columbia
OncoGenex Regains Rights to Custirsen from Teva BOTHELL Wash. and VANCOUVER, British Columbia, April 27, 2015 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 Conference call to be held on Thursday, March 26, 2015 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, March 26, 2015 OncoGenex Pharmaceuticals, Inc. (NASDAQ:
Read more →ACHVOncoGenex to Regain Rights to Custirsen from Teva Bothell WA and Vancouver BC
OncoGenex to Regain Rights to Custirsen from Teva Bothell WA and Vancouver BC, Dec. 30, 2014 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) to regain rights to custir
Read more →ACHVOncoGenex Announces Results from the Phase 2 Borealis-1 Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in
OncoGenex Announces Results from the Phase 2 Borealis-1 Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in Patients with L
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014 Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014 Conference call to be held on Thursday, October 30, 2014 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, October 30, 2014 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) toda
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, August 7, 2014 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today p
Read more →ACHVOncoGenex Pharmaceuticals Announces Pricing of $24 Million Underwritten Registered Direct Offering BOTHELL, Washington and VANCOUVER, British Columbia
OncoGenex Pharmaceuticals Announces Pricing of $24 Million Underwritten Registered Direct Offering BOTHELL, Washington and VANCOUVER, British Columbia, June 26, 2014 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has priced an underwritten registered di
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2014 Conference call to be held on Wednesday
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2014 Conference call to be held on Wednesday, April 30, 2014 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, April 30, 2014 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today p
Read more →ACHVOncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Cancer Bothell, WA and Vancouver, BC
OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Bothell, WA and Vancouver, BC, April 28, 2014 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced results from the Phase 3 SYNERGY t
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2013 Conference call to be held on Tuesday
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2013 Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, March 11, 2014 OncoGenex Pharmaceuticals, Inc. (NASDAQ: O
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call Conference call to be held on Thursday, November 7 at 4:30pm Easter
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference call to be held on Thursday, November 7 at 4:30pm Eastern Time BOTHELL, WA and VANCOUVER, British Columbia, Nov. 7, 2013 OncoGenex
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013 Conference call to be held on Thursday, August 8 at 4:30 pm Eastern Time BOTHELL, WA an
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013 Conference call to be held on Thursday, August 8 at 4:30 pm Eastern Time BOTHELL, WA and VANCOUVER, British Columbia, Aug. 8, 2013 OncoGenex Phar
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 Conference call to be held on Thursday, May 2 at 4:30pm Eastern Time BOTHELL, WA and VAN
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 Conference call to be held on Thursday, May 2 at 4:30pm Eastern Time BOTHELL, WA and VANCOUVER, British Columbia, May 2, 2013 OncoGenex Pharmac
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012 Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012 call to be held on Thursday, March 7, 2013 at 4:30 p.m. Eastern Time BOTHELL, WA., and VANCOUVER, British Columbia, March 7, 2013
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012 Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012 Conference call to be held on Thursday, November 8, 2012 at 4:30 p.m. Eastern Time BOTHELL, WA., and VANCOUVER, British Columbia, November 8, 2012 OncoGe
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427 Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427 Conference call to be held on Thursday, August 2, 2012 at 4:30 p.m. Eastern Time BOTHELL, WA., and VANCOUVER, Brit
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results and Reviews Clinical Development Highlights for First Quarter of 2012 Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Reports Financial Results and Reviews Clinical Development Highlights for First Quarter of 2012 Conference call to be held on Thursday, May 3, 2012 at 4:30 p.m. Eastern Time BOTHELL, WA., and VANCOUVER, British Columbia, May 3, 2012 OncoGenex
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Announces Full Exercise of Overallotment Option by Underwriters BOTHELL, Washington and VANCOUVER, British Columbia
OncoGenex Pharmaceuticals, Inc. Announces Full Exercise of Overallotment Option by Underwriters BOTHELL, Washington and VANCOUVER, British Columbia, March 23, 2012 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the underwriters of its previously announced
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering BOTHELL, Washington and VANCOUVER, British Columbia
OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering Washington and VANCOUVER, British Columbia, March 16, 2012 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has priced an underwritten public offering of 4,165,000 shares of its common stock
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock BOTHELL, Washington and VANCOUVER, British Columbia
OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock BOTHELL, Washington and VANCOUVER, British Columbia, March 15, 2012 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it commenced a public offering of its common stock. OncoGen
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2011 and Provides Update on Clinical Development Program Conference call to be held on Thursday
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2011 and Provides Update on Clinical Development Program Conference call to be held on Thursday, March 8, 2012 at 4:30 p.m. Eastern Time BOTHELL, WA., and VANCOUVER, British Columbia, Ma
Read more →ACHVClinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer OncoGenex Announces Plans to Initiate a
Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer OncoGenex Announces Plans to Initiate a Phase 2 Study of OGX-427 in Combination with Zytiga (ab
Read more →ACHVOncoGenex Pharmaceuticals Reports Financial Results for Third Quarter 2011 and Highlights Advancement of Portfolio Compounds Conference call to be held on Thursday
OncoGenex Pharmaceuticals Reports Financial Results for Third Quarter 2011 and Highlights Advancement of Portfolio Compounds Conference call to be held on Thursday, November 3, 2011 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, November 3, 2011 OncoG
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities BOTHELL, WA and VANCOUVER, BC
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities BOTHELL, WA and VANCOUVER, BC, August 4, 2011 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an update on current events and activitie
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2011 and Provides Update on Plans for the Phase 3 Prostate Cancer SATURN Clinical Trial BOTHELL, WA., and VANCOUVER, British Columbia
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2011 and Provides Update on Plans for the Phase 3 Prostate Cancer SATURN Clinical Trial BOTHELL, WA., and VANCOUVER, British Columbia, May. 9, 2011 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2010 and Provides Update on Custirsen Clinical Development Program BOTHELL, WA., and VANCOUVER, British Columbia
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year Provides Update on Custirsen Clinical Development Program BOTHELL, WA., and VANCOUVER, British Columbia, Mar. 10, 2011 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its fourt
Read more →ACHVOncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer BOTHELL, WA, and VANCOUVER
OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer BOTHELL, WA, and VANCOUVER, November 8, 2010 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the appointment of Michelle Burris to the position of exe
Read more →ACHVOncoGenex Reports Third Quarter Financial Results Conference Call on Thursday
OncoGenex Reports Third Quarter Financial Results Conference Call on Thursday, November 4, 2010 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, November 4, 2010 OncoGenex Pharmaceuticals, Inc. ( OncoGenex or the Company ) (NASDAQ: OGXI) today reported unaudited financial
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering BOTHELL, WA, and VANCOUVER
OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering BOTHELL, WA, and VANCOUVER, October 22, 2010 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has completed a public offering of 3,174,602 units at a price to the public of $15.75 per unit
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering BOTHELL, WA, and VANCOUVER
OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering BOTHELL, WA, and VANCOUVER, October 19, 2010 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has priced a public offering of 3,174,602 units, with each unit consisting of one share of the
Read more →ACHVOncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering BOTHELL, WA, and VANCOUVER
OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering BOTHELL, WA, and VANCOUVER, October 18, 2010 (Canada NewsWire via COMTEX News Network) OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it is commencing a public offering of its common stock
Read more →ACHVJournal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial Randomized Phase 2 Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate C
Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial Randomized Phase 2 Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Chi K.N., et al. JCO Sep 20, 2010: 4247-4254 BOTH
Read more →ACHVTEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER Jerusalem, Israel, Bothell, WA, and Vancouver, Canada
TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER Jerusalem, Israel, Bothell, WA, and Vancouver, Canada, September 30, 2010 Teva Pharmaceuticals Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc.
Read more →ACHVOncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced Prostate Cancer BOTHELL, WA, and VANCOUVER, CANADA
OncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced Prostate Cancer BOTHELL, WA, and VANCOUVER, CANADA, September 27, 2010 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of a randomi
Read more →ACHVOncoGenex Adds David V. Smith to the Board of Directors BOTHELL, WA and VANCOUVER, BC
OncoGenex Adds David V. Smith to the Board of Directors BOTHELL, WA and VANCOUVER, BC August 10, 2010 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that the Company has appointed Mr. David V. Smith to its board of directors. Mr. Smith brings to the board subs
Read more →ACHVOncoGenex Reports Second Quarter Financial Results Conference Call on Thursday
OncoGenex Reports Second Quarter Financial Results Conference Call on Thursday, August 5, 2010 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, August 5, 2010 OncoGenex Pharmaceuticals, Inc. ( OncoGenex or the Company ) (NASDAQ: OGXI) today reported unaudited financial re
Read more →ACHVOncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer BOTHELL, WA, and VANCOUVER
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer BOTHELL, WA, and VANCOUVER, Jun 21, 2010 (Canada NewsWire via COMTEX News Network) OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of a Phase 3
Read more →ACHVOncoGenex Pharmaceuticals Announces Final Results from Phase 1 Trial Evaluating OGX-427 as a Treatment for Solid Tumors Results Presented at ASCO 2010 Annual Meeting Confirm Acceptable Safety Profile and Evidence of Biol
OncoGenex Pharmaceuticals Announces Final Results from Phase 1 Trial Evaluating OGX-427 as a Treatment for Solid Tumors Results Presented at ASCO 2010 Annual Meeting Confirm Acceptable Safety Profile and Evidence of Biological Activity Including Declines in Circulating Tumor C
Read more →ACHVOncoGenex Reports First Quarter Financial Results Conference Call on Thursday
OncoGenex Reports First Quarter Financial Results Conference Call on Thursday, May 6, 2010 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, May 6, 2010 OncoGenex Pharmaceuticals, Inc. ( OncoGenex or the Company ) (NASDAQ: OGXI) today reported unaudited financial results f
Read more →ACHVData from OncoGenex Pharmaceuticals Product Candidate OGX-427 to be Presented at the American Society of Clinical Oncology Annual Meeting BOTHELL, WA and VANCOUVER
Data from OncoGenex Pharmaceuticals Product Candidate OGX-427 to be Presented at the American Society of Clinical Oncology Annual Meeting BOTHELL, WA and VANCOUVER, March 25, 2010 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that final results from a Phase 1
Read more →ACHVOncoGenex Adds Biopharmaceutical Industry Veterans to the Board of Directors BOTHELL, WA and VANCOUVER, BC
OncoGenex Adds Biopharmaceutical Industry Veterans to the Board of Directors BOTHELL, WA and VANCOUVER, BC March 24, 2010 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that the Company has appointed Dr. Jack Goldstein and Ms. H. Stewart Parker to its board o
Read more →ACHVOncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2009 and Provides Outlook for 2010 Conference Call on Monday
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2009 and Provides Outlook for 2010 Conference Call on Monday, March 8, 2010 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, March 8, 2010 OncoGenex Pharmaceuticals, Inc. ( OncoGenex or the Company )
Read more →ACHVThe European Medicines Agency is in Overall Agreement with OncoGenex Pharmaceuticals Development Plan for OGX-011 in Patients with Metastatic Castrate-Resistant Prostate Cancer BOTHELL, WA and VANCOUVER, BC
The European Medicines Agency is in Overall Agreement with OncoGenex Pharmaceuticals Development Plan for OGX-011 in Patients with Metastatic Castrate-Resistant Prostate Cancer BOTHELL, WA and VANCOUVER, BC February 25, 2010 OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced t
Read more →ACHVOncoGenex Announces Departure of Chief Financial Officer BOTHELL, WA and VANCOUVER, BC
OncoGenex Announces Departure of Chief Financial Officer BOTHELL, WA and VANCOUVER, BC February 25, 2010 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company and Steve Anderson, its chief financial officer, have agreed that he will leave the Company
Read more →ACHVOncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding BOTHELL, WA and VANCOUVER, BC
OncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding BOTHELL, WA and VANCOUVER, BC January 6, 2010 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that a randomized, controlled, investigator-s
Read more →ACHVOncoGenex Reports Third Quarter 2009 Financial Results Conference Call on Thursday
OncoGenex Reports Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, November 5, 2009 OncoGenex Pharmaceuticals, Inc. ( OncoGenex or the Company ) (NASDAQ: OGXI) today reported unaudited fina
Read more →ACHVFDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line Chemotherapy BOTHELL, WA, and VANCOUVER
FDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line Chemotherapy BOTHELL, WA, and VANCOUVER October 6, 2009 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that OGX-011, also known as custirsen sodium, received an additional F
Read more →ACHVOncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer BOTHELL, WA, and VANCOUVER
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer BOTHELL, WA, and VANCOUVER August 13, 2009 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the first patient has been dosed in an open label, dose-escalation,
Read more →ACHVOncoGenex Reports Second Quarter 2009 Financial Results Conference Call on Thursday
OncoGenex Reports Second Quarter 2009 Financial Results Conference Call on Thursday, August 6, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, August 6, 2009 OncoGenex Pharmaceuticals, Inc. ( OncoGenex or the Company ) (NASDAQ: OGXI) today reported unaudited financi
Read more →ACHVOncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering BOTHELL. WA AND VANCOUVER, July 24, 2009 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has completed its registered direct offering, previously announced on July 20, 2009, of 47
Read more →ACHVOncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock BOTHELL, WA and VANCOUVER
Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock WA and VANCOUVER July 20, 2009 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today it has entered into purchase agreements with certain institutional investors for the sale of 475,000 shares of its c
Read more →ACHVOncoGenex Pharmaceuticals Files Shelf Registration Statement BOTHELL, WA, and VANCOUVER
OncoGenex Pharmaceuticals Files Shelf Registration Statement BOTHELL, WA, and VANCOUVER June 26, 2009 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has filed a shelf registration statement on Form S-3 with the US Securities and Exchange Commission and a
Read more →ACHVOncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer BOTHELL, WA, and
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer BOTHELL, WA, and VANCOUVER June 24, 2009 OncoGenex Pharmaceuticals, Inc.
Read more →ACHVOncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer Webcast at 7:10 p.m. Eastern Time Today BOTHELL, WA, and VANCOUVER
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer Webcast at 7:10 p.m. Eastern Time Today BOTHELL, WA, and VANCOUVER, May 30, 2009 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) to
Read more →ACHVOncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427 BOTHELL, WA, and VANCOUVER
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427 BOTHELL, WA, and VANCOUVER, May 14, 2009 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the release
Read more →ACHVONCOGENEX RECEIVES CONFIRMATION FROM FDA ON THE DESIGN OF A SECOND PHASE 3 TRIAL EVALUATING OGX-011 FOR THE TREATMENT OF ADVANCED PROSTATE CANCER FDA confirms durable pain palliation as an acceptable primary endpoint for
ONCOGENEX RECEIVES CONFIRMATION FROM FDA ON THE DESIGN OF A SECOND PHASE 3 TRIAL EVALUATING OGX-011 FOR THE TREATMENT OF ADVANCED PROSTATE CANCER FDA confirms durable pain palliation as an acceptable primary endpoint for a regulatory submission in support of market April 28, 2
Read more →ACHVOncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 Conference Call on Wednesday
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 Conference Call on Wednesday, March 11, 2009 at 4:30 p.m. Eastern Time BOTHELL, Washington and VANCOUVER, British Columbia, Canada March 11, 2009 OncoGenex Pharmaceutical
Read more →ACHVOncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer BOTHELL, WA, and VANCOUVER, Feb. 4/PR Newswire-First Call/ -- OncoGenex Pharmaceuticals,
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer BOTHELL, WA, and VANCOUVER, Feb. 4/PR Newswire-First Call/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI - News) today announced the two-year s
Read more →Competitive Position
How ACHV ranks across every disease it competes inCompetitive Position is a premium feature
See how ACHV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial